Abbisko Cayman Limited (HK:2256) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbisko Cayman Limited has announced the initiation of a Phase II clinical trial for its oral drugs ABSK061 and ABSK043, aimed at treating metastatic or unresectable solid tumors with FGFR2/3 alterations. These drugs have shown promising anti-tumor activity and a favorable safety profile in previous studies, making this trial a significant development for potential cancer treatments. Investors are advised to be cautious as the drugs are still under clinical evaluation.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.